Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2015: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017 - 2016 - 2015 - 2014

August 2015 Scleroderma News

First Patient Treated in the U.S. STAR Trial. Cytori has successfully begun its first ever U.S. approval trial and consistent with their experience in treating scleroderma in Europe, the patient tolerated the procedure well. Cytori, 08/25/2015. (Also see Scleroderma Clinical Trials: ADRC Injections/STAR)

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR). The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma., 08/24/2015. (Also see Scleroderma Clinical Trials: ADRC Injections/STAR)

Cancer Risk Factors in Patients With Scleroderma. Increased age at scleroderma onset was strongly associated with cancer risk. Medscape, 06/15/2015. (Also see Cancer and Scleroderma)

Study Discusses Three Therapies for Digital Ulcers in Systemic Scleroderma (SSc). Nonpharmacologic, pharmacologic, and surgical interventions are important for managing the patients who are affected by this complication. Scleroderma News, 07/01/2015. (Also see Treatments for Digital Ulcers)

Early Detection of PAH in Systemic Sclerosis Achieved Using Ultrasound Technology. Using right heart catheterization as the gold standard in all patients showed that stress Doppler-echocardiography markedly improved sensitivity in detecting manifest Pulmonary Hypertension. Scleroderma News, 06/22/2015. (Also see Diagnosis of Scleroderma Heart Involvement and Diagnosis of Pulmonary Hypertension)

Antiphospholipid Antibody Levels High In Systemic Scleroderma (SSc) Patients. Patients with SSc commonly express antiphospholipid antibodies, although not all are affected by the antiphospholipid syndrome. Scleroderma News, 06/22/2015. (Also see Antiphospholipid Syndrome)

Study Shows Treatment with Fresolimumab Able to Reduce Skin Scarring in Systemic Scleroderma patients. Fresolimumab, a drug agent that targets a chemical mediator in the body called TGF-beta, is able to block scarring which could mean a major treatment advance for scarring-mediated organ dysfunction. Scleroderma News, 06/23/2015. (Also see Causes of Scleroderma: Molecular Defect and Skin Fibrosis)

Systemic Sclerosis Patients’ Intestinal Microbiome Found To Be Enriched by Inflammatory Bacteria. Patients with systemic sclerosis harbor a unique microbiome in their gut when compared to healthy individuals, which may contribute to patients’ immune dysfunction. Scleroderma News, 06/17/2015. (Also see Bowel Dysfunction)

A Right Ventricular (RV) Diastolic Impairment is Common in Systemic Sclerosis (SSc) and is Associated with Other Target-Organ Damage. RV is commonly affected in SSc with predominant impaired diastolic function and several factors, including primary heart, lung vascular disease and pulmonary hypertension, contribute to such impairment. Seminars in Arthritis and Rheumatism, 07/07/2015. (Also see Cardiac (Heart) Involvement)

A comparison between general rheumatologists and scleroderma (SSc) experts with respect to following systemic sclerosis guidelines. Compared to SSc experts, general rheumatologists did not differ in their practices for many SSc guidelines despite the fact that they do not see many SSc patients when compared to SSc experts, but there was site variability. Clinical and Experimental Rheumatology Online, 07/02/2015. (Also see Scleroderma Experts)

Consensus best practice pathway of the UK Systemic Sclerosis Study Group: digital vasculopathy in systemic sclerosis. A number of treatment algorithms are provided that are intended to provide the clinician with accessible reference tools for use in daily management. PubMed, Rheumatology (Oxford), 06/26/2015. (Also see Vascular Involvement)

Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA (miRNA) in systemic sclerosis. Circulating miRNA profiles differ between limited and diffuse scleroderma patients and between patients with different autoantibodies. PubMed, Rheumatology (Oxford), 07/10/2015. (Also see Antibodies)

Go to Scleroderma Medical News: July 2015
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.